Aegerion Pharmaceuticals (AEGR) Misses Q3 EPS by 6c, Lowers JUXTAPID Guidance

Aegerion Pharmaceuticals (NASDAQ: AEGR) reported Q3 EPS of ($0.20), $0.06 worse than the analyst estimate of ($0.14). Revenue for the quarter came in at $43.7 million versus the consensus estimate of $48.6 million.

2014 and 2015 Financial Guidance

Aegerion stated the following financial guidance:

Aegerion now expects full-year JUXTAPID net product sales to be between $150 and $160 million, revised from the previous expectation of the lower end of the range of between $180 and $200 million.
Aegerion now expects total operating expenses, excluding stock-based compensation, of between $135 and $145 million for FY 2014. The Company expects GAAP operating expenses in 2014, including stock-based compensation, to be between $165 and $175 million.
Aegerion expects 2015 revenue growth of between 30% and 40% over 2014 projected revenue, taking into account forecasted prescription rates, drop-out rates, conversion trends, and the potential slowing impact on new patients starts following the anticipated launch of the PCSK-9 class of drugs in mid-2015, an impact Aegerion believes will ultimately be offset, in whole or part, through the identification of more HoFH patients as a result of the greater disease awareness likely to follow introduction of PCSK-9 inhibitors.

For earnings history and earnings-related data on Aegerion Pharmaceuticals (AEGR) click here.

You May Also Be Interested In

• AbbVie (ABBV) Tops Q1 EPS by 4c, Raises Guidance
• Oppenheimer Holdings (OPY) Reports Q1 EPS of $2.37
• Midland States Bancorp, Inc. (MSBI) Misses Q1 EPS by 19c